Peter Murray, Editor

About the Author Peter Murray, Editor


Roku Inc (ROKU) 3Q Earnings Give This Top Analyst a Bit More Confidence

Mark Mahaney believes the company is executing on its long-term vision, but remains sidelined.

Read more

Top Analyst Pounds the Table on Activision Blizzard, Inc. (ATVI)

Piper Jaffray’s top analyst Michael Olson was out pounding the table on shares of Activision Blizzard, …

Read more

Alibaba Group Holding Ltd (BABA) Nailed It Again; Top Analyst Reiterates Buy

Alibaba Group Holding Ltd (NYSE:BABA) reported another strong set of headline earnings, with results well …

Read more

Maxim Reiterates Buy On ContraVir Pharmaceuticals Inc (CTRV) Following Corporate Update

Maxim analyst Jason Kolbert is out today with a new research note on shares of ContraVir Pharmaceuticals …

Read more

How Analysts View Netflix, Inc. (NFLX) Post 3Q:17 Results

In a research note released Tuesday, Aegis analyst Victor Anthony reiterated a Hold rating on …

Read more

Cantor Pounds the Table on Valeant Pharmaceuticals Intl Inc (VRX)

Fears about financial control should be a buying opportunity in Valeant stock, says Cantor.

Read more

Maxim Pounds the Table on MannKind Corporation (MNKD)

Will Mannkind file bankruptcy? Jason Kolbert says no.

Read more

Fixed: Canaccord Highlights Upcoming Catalysts For Palatin Technologies, Inc. (PTN) Bulls

John Newman continues to expect NDA in 2018 for bremelanotide, while pipeline moves forward.

Read more

Walt Disney Co’s (DIS) Soggy Outlook Tests Investors Patience; Credit Suisse Weighs in

Credit Suisse remains bullish on Walt Disney despite earnings warning.

Read more

The Medicines Company (MDCO): How Much Vabomere Worth?

This morning, The Medicines Company (NASDAQ:MDCO) reported that the FDA approved its urinary tract infection treatment Vabomere, …

Read more